Travere Therapeutics, Inc. (TVTX)
TVTX Stock Price Chart
Explore Travere Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze TVTX price movements and trends.
TVTX Company Profile
Discover essential business fundamentals and corporate details for Travere Therapeutics, Inc. (TVTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Nov 2012
Employees
385.00
Website
https://www.travere.comCEO
Eric M. Dube
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
TVTX Financial Timeline
Browse a chronological timeline of Travere Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 18 Feb 2026
Upcoming earnings on 30 Oct 2025
EPS estimate is -$0.32.
Earnings released on 6 Aug 2025
EPS came in at -$0.14 surpassing the estimated -$0.28 by +50.00%, while revenue for the quarter reached $114.45M , beating expectations by +14.97%.
Earnings released on 1 May 2025
EPS came in at -$0.47 surpassing the estimated -$0.55 by +14.55%, while revenue for the quarter reached $81.73M , missing expectations by -7.96%.
Earnings released on 20 Feb 2025
EPS came in at -$0.73 falling short of the estimated -$0.58 by -25.86%, while revenue for the quarter reached $74.79M , beating expectations by +3.33%.
Earnings released on 31 Oct 2024
EPS came in at -$0.70 matching the estimated -$0.70, while revenue for the quarter reached $62.90M , missing expectations by -11.96%.
Earnings released on 1 Aug 2024
EPS came in at -$0.90 falling short of the estimated -$0.87 by -3.45%, while revenue for the quarter reached $54.12M , missing expectations by -6.33%.
Earnings released on 6 May 2024
EPS came in at -$1.76 falling short of the estimated -$0.98 by -79.59%, while revenue for the quarter reached $41.37M , missing expectations by -3.44%.
Earnings released on 15 Feb 2024
EPS came in at -$1.16 surpassing the estimated -$1.27 by +8.66%, while revenue for the quarter reached $45.06M , beating expectations by +8.55%.
Earnings released on 7 Nov 2023
EPS came in at -$1.17 falling short of the estimated -$1.09 by -7.34%, while revenue for the quarter reached $37.10M , missing expectations by -68.38%.
Earnings released on 3 Aug 2023
EPS came in at -$1.13 surpassing the estimated -$1.16 by +2.59%, while revenue for the quarter reached $59.70M , beating expectations by +11.15%.
Earnings released on 4 May 2023
EPS came in at -$1.27 falling short of the estimated -$1.18 by -7.63%, while revenue for the quarter reached $56.99M , beating expectations by +12.61%.
Earnings released on 23 Feb 2023
EPS came in at -$1.03 surpassing the estimated -$1.04 by +0.96%, while revenue for the quarter reached $55.87M , beating expectations by +5.38%.
Earnings released on 27 Oct 2022
EPS came in at -$1.09 falling short of the estimated -$0.97 by -12.37%, while revenue for the quarter reached $53.50M , missing expectations by -1.15%.
Earnings released on 4 Aug 2022
EPS came in at -$1.05 falling short of the estimated -$0.94 by -11.70%, while revenue for the quarter reached $54.17M , beating expectations by +9.14%.
Earnings released on 5 May 2022
EPS came in at -$1.20 falling short of the estimated -$0.85 by -41.18%, while revenue for the quarter reached $48.49M , missing expectations by -7.10%.
Earnings released on 24 Feb 2022
EPS came in at -$0.84 falling short of the estimated -$0.72 by -16.67%, while revenue for the quarter reached $57.25M , missing expectations by -0.95%.
Earnings released on 28 Oct 2021
EPS came in at -$0.59 surpassing the estimated -$0.72 by +18.06%, while revenue for the quarter reached $68.22M , beating expectations by +29.59%.
Earnings released on 29 Jul 2021
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%, while revenue for the quarter reached $54.62M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at -$0.96 falling short of the estimated -$0.56 by -71.43%, while revenue for the quarter reached $47.41M , beating expectations by +31.31%.
Earnings released on 1 Mar 2021
EPS came in at -$2.37 falling short of the estimated -$0.43 by -451.16%, while revenue for the quarter reached $50.98M .
Earnings released on 5 Nov 2020
EPS came in at -$0.44 surpassing the estimated -$0.52 by +15.38%, while revenue for the quarter reached $51.14M .
TVTX Stock Performance
Access detailed TVTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.